-
FES PET/CT in Endocrine Refractory Breast Cancer
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study ...
David Mankoff
See if you qualify
-
UPCC 16517: A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in ...
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic ...
Joshua Bauml
-
UPCC 31216: Phase I/II Trial of Regorafenib Hydroxychloroquine and Entinostat in Metastatic Colorectal Cancer
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with ...
Peter O'Dwyer
-
METAMORPH
This is a cohort study of women with suspected or confirmed recurrent breast cancer, with accessible tumor by standard clinical ...
-
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with ...
Request for collaborative review: WIRB serving as IRB of record.
Gerald Linette
-
Pragmatic Phase Iii Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation ...
This is a pragmatic randomized clinical trial in which patients with locally advanced breast cancer will be randomized to either ...
Justin Bekelman
-
UPCC 05122: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously ...
The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and ...
Payal Shah
-
UPCC 15820: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone ...
The purpose of this study is to see if niraparib added to a standard treatment (abiraterone acetate and prednisone) will ...
-
“The Shift Worker’s Microbiome”
We are looking for healthy males, age 40-59 years old, non-smoking un-medicated who work the "shift-work" schedule (>3 shifts per ...
Lavenia M Banas, Rn
-
UPCC 13118: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant Palbociclib and Avelumab for ...
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in ...
Angela De Michele
Showing - of trials